The drug company Zydus Cadila on Monday said it had received approval from the US health director to market Sitagliptin, a drug shown to treat diabetes. The company said its subsidiary had received approval from the United States Food and Drug Administration (FDA) for its new application for Sitagliptin tablets of 25, 50 and 100 mg. On October 31, 2020, Zydus filed a new drug application (NDA) with the USFDA seeking approval to sell Sitagliptin base 25, 50 and 100 mg tablets. Also read : Only second dose of COVID-19 vaccine at community centers in Mumbai on September 4: BMC The NDA received temporary approval after completing the first review round on September 2, 2021, Zydus Cadila said. Zydus Cadila acquires, develops, manufactures, and sells a wide range of therapies including small molecule drugs, biologic therapeutics, and vaccines. The group employs about 23,000 people worldwide. The group employs about 23,000 people worldwide. Also read : Ami Organics IPO GMP, Registration, Company Review, Risks. Last Opportunity to Invest Today
